ATHENS, Ga–(BUSINESS WIRE)–ArunA
Bio, a leader in the development of exosomes and exosome
therapeutics for the treatment of neurodegenerative disorders, today
announced the appointment of Al Medwar as Executive Vice President,
Corporate and Commercial Development. Mr. Medwar joins the company and
its leadership team contributing over 30 years of pharmaceutical
industry experience.
Mr. Medwar joins recently appointed Chief Executive Officer, Dr. Mark A.
Sirgo, and team as they focus on progressing ArunA’s neural exosome
platform toward commercialization, including partnerships with companies
in the CNS therapeutic area.
“I am pleased to have Al join the leadership team at ArunA Bio as we
move aggressively to utilize our neural exosome platform to develop
novel therapeutics to treat serious neurodegenerative disorders through
both our internal pipeline and industry collaborations,” said Dr. Sirgo.
“Al played a significant role in building BioDelivery Sciences into a
fully integrated pharmaceutical company based on a platform technology.
I look forward to successfully collaborating with Al again in this new
and exciting venture.”
Prior to joining the company, Mr. Medwar was Senior Vice President,
Corporate and Business Development for BioDelivery Sciences (Nasdaq:
BDSI), where he spent eleven years and played a key role in building the
company from a development to a commercial stage enterprise and in
securing a number of licensing and partnership deals. In his capacity at
BioDelivery Sciences, Mr. Medwar also led investor and public relations
working closely with the investor and analyst communities. While at EMD
Pharmaceuticals, the U.S. subsidiary of Merck KGaA, Mr. Medwar served as
Head of Oncology Marketing, where he was responsible for developing the
global market for a pipeline of immuno-oncology products. Earlier in his
career, he was also the Marketing Director for Triangle Pharmaceuticals,
a start-up company focusing on the development and commercialization of
compounds for HIV and hepatitis. Mr. Medwar’s pharmaceutical career
began in sales at Glaxo Wellcome. He received a BS degree from Cornell
University and an MBA from Bentley University.
About ArunA Bio
ArunA Bio is harnessing the natural abilities of neural exosomes to
cross the blood brain barrier and enhance the body’s anti-inflammatory,
self-repair and protective mechanisms to treat a range of
neurodegenerative disorders. We are leveraging our proprietary exosomes
and manufacturing platform to create synergistic therapies by enhancing
our exosomes with small molecules, RNA, oligonucleotides and antibodies.
For more information, please visit www.arunabio.com.
Contacts
MacDougall
Lauren Arnold
larnold@macbiocom.com
781-235-3060